| Similar Articles |
|---|
 |
CIO
October 15, 2002
Stephanie Overby |
They Want a New Drug In the race to develop new pharmaceuticals more quickly, companies are introducing new IT tools. But the tools can't do it alone. CIOs need to change the way people do their work.   |
Pharmaceutical Executive
December 1, 2012
Torrey et al. |
Transforming Drug Development: A Case Study Eli Lilly's pioneering pact with leading CRO Covance made big news when it happened. Four years later, both parties can point to metrics that suggest the benefit is mutual. |
The Motley Fool
March 23, 2011
Brian Orelli |
Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own. |
BusinessWeek
February 25, 2010
Weintraub & Tirrell |
Eli Lilly's Drug Assembly Line Faced with expiring patents that could weaken sales, Lilly is reorganizing for speed. |
The Motley Fool
January 5, 2004
Alyce Lomax |
Side Effects at Lilly? Growing profits, with earnings pains. |
The Motley Fool
October 21, 2010
Brian Orelli |
Nice Earnings, Eli Lilly, but ... Eli Lilly trounced analysts' earnings estimates today, but investors sighed -- and for good reason. |
Fast Company
April 2002
Bill Breen |
Lilly's R&D Prescription How does pharmaceutical giant Eli Lilly accelerate the pace while reducing the cost of innovation? By corralling scientists around the world in a Web-based system of eR&D... |
The Motley Fool
July 26, 2007
Brian Lawler |
Lilly Doesn't Wilt The second quarter was another good one for Eli Lilly. Top-line and bottom-line both grew. |
The Motley Fool
January 28, 2011
Brian Orelli |
Avoid This Falling Knife for Now 2011 could be just the start of a long slide for Lilly. And 2012 will see difficult year-over-year comparison. |
The Motley Fool
April 15, 2005
Brian Gorman |
Relief Pitch for Eli Lilly A ruling upholding the Zyprexa patent is good news for Lilly, but promising drugs in the pipeline are even more encouraging. Investors, take note. |
The Motley Fool
August 4, 2010
Ryan McBride |
How Eli Lilly Let a Billion-Dollar Molecule Slip Away, and Make a Fortune for Vertex The remains of Lilly's partnership with Vertex Pharmaceuticals. |
The Motley Fool
May 31, 2007
Brian Lawler |
Dueling Fools: Eli Lilly Bear Well-managed companies don't always make for good investments. This pharmaceutical powerhouse is a good example. |
The Motley Fool
May 31, 2007
Brian Lawler |
Dueling Fools: Eli Lilly Bear Rebuttal Shareholders who buy into Lilly at its current valuation just won't have the same opportunity for stock price appreciation as those who bought shares in the late '80s or early '90s. |
The Motley Fool
April 22, 2008
Brian Lawler |
Lilly in Full Financial Bloom Pharmaceutical Eli Lilly boosts revenue in the first quarter, but its drug-pipeline progress falls short of spectacular. |
Pharmaceutical Executive
November 1, 2008
Joanna Breitstein |
Gilding Lilly With new CEO John Lechleiter in charge, can Lilly find its way back from the edge? |
The Motley Fool
December 12, 2008
Brian Orelli |
A Long-Term Play for Your Port Long-term prospects look better than the near term ones for Eli Lilly and its investors. |
The Motley Fool
August 13, 2010
Brian Orelli |
Already a Slippery Slope for Eli Lilly The company gets a whiff of what its patent cliff might be like. |
The Motley Fool
July 21, 2005
Stephen D. Simpson |
Tiger Lilly or Wilting Daisy? For now, Lilly seems to me to be a middle-of-the-road type of pharmaceutical stock. There are plenty of worse ideas out there, but there are better ideas, as well. |
The Motley Fool
January 30, 2008
Brian Lawler |
Eli Lilly Is Resilient Proving that not every sector is affected by downturns, Eli Lilly released its fourth-quarter results yesterday, showing a bit of top-line growth. |
The Motley Fool
October 20, 2006
Brian Lawler |
Lilly Pads Its Earnings Lilly reports third-quarter 2006 numbers and gobbles up Cialis. Investors, take note. |
The Motley Fool
October 22, 2007
Brian Lawler |
Modest Numbers From Eli Lilly Its sales were up for the quarter, but a new drug might be the best indicator of its prospects. Lilly's pipeline will dictate its near-term future. |
The Motley Fool
December 29, 2006
Brian Lawler |
Lilly's Patents Stay in Bloom Even with upcoming patent expiries, Lilly isn't in nearly the same desperate situation that some of its large-cap pharma peers will be dealing with in the upcoming years. Investors, take note. |
The Motley Fool
January 26, 2005
Stephen D. Simpson |
Lilly's No Wallflower The drugmaker posts tepid results as it bides time before new products hit the market. Lilly's valuation suggests that Wall Street has faith that those new drugs will come through. |
BusinessWeek
August 27, 2009 |
Companies That Are Opening Up with Collaborative Research These three companies are examples of the new collaborative efforts taken to spur innovation. |
The Motley Fool
October 24, 2008
Brian Orelli |
Lilly's Results Run the Gamut The company's GAAP EPS and adjusted EPS are at polar extremes. |
The Motley Fool
June 13, 2008
Brian Lawler |
Lilly Patches Its Pipeline An early-stage compound joins the pharmaceutical's upcoming roster. |
ifeminists
December 28, 2005
Tony Zizza |
If Depression Hurts, Eli Lilly Is Killing Us Eli Lilly's latest marketing campaign is a form of propaganda that speaks to how low Big Pharma will go to keep Americans in chemical handcuffs. |
The Motley Fool
May 31, 2007
Ryan Fuhrmann |
Dueling Fools: Eli Lilly Bull Thanks to a couple of recent developments and a focus on research & development, the pharma giant is a worthy contender for health-care exposure in investors' portfolios. |
The Motley Fool
July 10, 2008
Brian Lawler |
Lilly Targets a Tiny Prize As drugmakers go, this acquisition's a value meal. |
The Motley Fool
June 30, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Major Wall Street investment house Soleil Securities downgraded Eli Lilly shares to "sell." |
The Motley Fool
July 23, 2010
Brian Orelli |
Eli Lilly Looks Great Today, but I'm Concerned About Tomorrow Eli Lilly is firing on all cylinders, but is there a blowout in its future? |
The Motley Fool
May 18, 2005
Brian Gorman |
Lilly Launches Automation Eli Lilly's drive to improve efficiency makes the company worth watching. |
The Motley Fool
December 10, 2004
Brian Gorman |
Cardinal Picks a Lilly Cardinal Health's deal with Lilly suggests the new fee-for-service model is gaining traction. |
The Motley Fool
April 19, 2011
Brian Orelli |
See You on the Other Side of the Cliff Lilly beats, but there's still a lot of unknowns. Can the company continue the trend through the patent cliff? |
Chemistry World
July 24, 2013
Andy Extance |
Lilly freezes pay as patent cliff looms The company is looking to save money ahead of the imminent expiration of two key patents, from which it faces a 20% fall in revenue. |
The Motley Fool
February 25, 2008
Brian Lawler |
The Most Interesting FDA Review for 2008 Eli Lilly preps for an upcoming FDA review of its top pipeline drug, the blood thinner prasugrel. |
The Motley Fool
October 21, 2004
Roger Nusbaum |
Pictures of Lilly Eli Lilly's numbers get lost in the wake of Merck and Pfizer. While the market waits for drug stocks to recover, investors can collect Lilly's 2.5%, safe, dividend. |
The Motley Fool
January 28, 2010
Brian Orelli |
The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren. |
The Motley Fool
September 5, 2007
Billy Fisher |
Lilly's Pipeline Continues to Produce Another schizophrenia drug from the company shows promise in a clinical trial, prompting the company to plan additional trials. This is the latest good news in what has been a good year for Lilly. |
The Motley Fool
January 26, 2006
Stephen D. Simpson |
Will New Drugs Gild Lilly? Although Lilly's late-stage pipeline is weak, newer drugs should still be able to grow. Investors, this is still a mediocre investment option. |
The Motley Fool
May 31, 2007
Ryan Fuhrmann |
Dueling Fools: Eli Lilly Bull Rebuttal Investors need to keep looking for further proof that Lilly's valuation premium to its peers is fully warranted, but if current trends are any indication, its growth prognosis could lead the industry. |
The Motley Fool
October 7, 2008
Brian Orelli |
Eli Lilly's Risky Gamble Eli Lilly is desperate, and the high acquisition price of ImClone shows it. |
The Motley Fool
June 8, 2007
Brian Lawler |
Lilliputian Attack on Lilly? While every investor should have some degree of exposure to pharmaceutical stocks, recent patent decisions in two of the biggest pharmaceutical drugs markets should serve as a warning of the potential litigation dangers when investing in some of the sector's giants. |
The Motley Fool
June 14, 2004
Brian Gorman |
Elan Teams Up With Lilly The companies' manufacturing agreement may be more of a positive sign for Eli Lilly than it is for Elan. |
The Motley Fool
January 31, 2007
Brian Lawler |
Lilly Floats Atop Rivals The large-cap pharma posts slow, steady growth. Investors, take note. |
The Motley Fool
May 1, 2007
Brian Lawler |
Cardiome Plays Dealmaker Cardiome signs a deal to develop one of Eli Lilly's drug candidates. Investors, take note. |
The Motley Fool
June 25, 2008
Brian Lawler |
Why the Lilly Delay, FDA? A government review of the company's top drug candidate gets pushed back. |
The Motley Fool
September 30, 2008
Brian Lawler |
No Approval for You ... Yet The FDA makes Eli Lilly wait for word on a lead drug. |
Bio-IT World
November 2006
Wendy Wolfson |
Oracle OpenWorld 2006: Pharma Stuck on Semantic Web At the recent Oracle OpenWorld conference, pharma executives offered evidence that some, at least, are using the semantic web to work smarter and lower drug development costs. |
The Motley Fool
May 24, 2011
Brian Orelli |
If at First You Don't Succeed, Spin It Off Eli Lilly ditches Xigris by spinning off BioCritica. |
